Isoray Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Isoray.

Isoray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Isoray.

Isoray, Inc. (NYSEAMERICAN:ISR) released its earnings results on Thursday, September, 17th. The healthcare company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. The healthcare company earned $2.28 million during the quarter, compared to analyst estimates of $2.77 million.
View Isoray's earnings history.

Isoray issued an update on its first quarter 2021 After-Hours earnings guidance on Thursday, September, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.5 million, compared to the consensus revenue estimate of $3.1 million.

3 analysts have issued 1 year price objectives for Isoray's shares. Their forecasts range from $1.25 to $1.75. On average, they anticipate Isoray's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 278.4% from the stock's current price.
View analysts' price targets for Isoray.

Isoray saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 1,310,000 shares, a decrease of 12.7% from the September 15th total of 1,500,000 shares. Based on an average daily trading volume, of 351,500 shares, the days-to-cover ratio is presently 3.7 days.
View Isoray's Short Interest.

Some companies that are related to Isoray include Daxor (DXR), Daxor (DXR), TransEnterix (TRXC), TSO3 (TOS), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), American Medical Technologies (ADLI), Ansell (ANSLF), Ansell (ANN), ANSELL LTD/S (ANSLY), Borqs Technologies (BTAVF), Clover Co. Limited (CLV.AX) (CLV) and Commerzbank (CZMWY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), Opko Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Isoray's stock is owned by many different retail and institutional investors. Top institutional investors include Avantax Advisory Services Inc. (0.07%). Company insiders that own Isoray stock include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends for Isoray.

ISR stock was purchased by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc.. Company insiders that have bought Isoray stock in the last two years include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, and William Cavanagh.
View insider buying and selling activity for Isoray.

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ISR stock can currently be purchased for approximately $0.40.

Isoray has a market capitalization of $27.31 million. Isoray employs 53 workers across the globe.

The official website for Isoray is isoray.com.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.